Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia.
作者： A. K. Martin , B. Mowry
DOI: 10.1017/S0033291715001701
关键词:
摘要: Background A significant number of patients with schizophrenia fail to respond antipsychotic medication. Although several studies have investigated associated patient characteristics, the emerging findings from genetic offer further scope for study. Method In 612 detailed clinical information, common variants indexed by polygenic risk scores, and rare deletion duplication burden genomewide, we explored potential predictors alongside other established factors treatment resistance. Clinical outcomes resistance were also calculated using lifetime measures positive, negative/disorganized mood symptoms as well hospitalizations suicide attempts. Results Logistic regression models identified a relationship between total years formal schooling age at onset. Clinically, treatment-resistant characterized greater positive hospitalizations. Conclusions Taken together, these suggest specifically genomewide copy variants, may increase our understanding management schizophrenia.
uq.edu.au参考文章(44)
Patrick F Sullivan, Danielle Posthuma, Biological pathways and networks implicated in psychiatric disorders Current Opinion in Behavioral Sciences. ,vol. 2, pp. 58- 68 ,(2015) , 10.1016/J.COBEHA.2014.09.003
Robin M. Murray, Jim Van Os, Predictors of outcome in schizophrenia. Journal of Clinical Psychopharmacology. ,vol. 18, ,(1998) , 10.1097/00004714-199804001-00002
J Frank, M Lang, S H Witt, J Strohmaier, D Rujescu, S Cichon, F Degenhardt, M M Nöthen, D A Collier, S Ripke, D Naber, M Rietschel, Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients Molecular Psychiatry. ,vol. 20, pp. 150- 151 ,(2015) , 10.1038/MP.2014.56
Andreas Reichert, Susanne Kreiker, Claudia Mehler-Wex, Andreas Warnke, The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child and Adolescent Psychiatry and Mental Health. ,vol. 2, pp. 6- 6 ,(2008) , 10.1186/1753-2000-2-6
Vita Dolžan, Alessandro Serretti, Laura Mandelli, Jure Koprivšek, Matej Kastelic, Blanka Kores Plesničar, Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Progress in Neuro-psychopharmacology & Biological Psychiatry. ,vol. 32, pp. 1562- 1566 ,(2008) , 10.1016/J.PNPBP.2008.05.022
Andrew Kenneth Martin, Gail Robinson, David Reutens, Bryan Mowry, None, Cognitive and structural neuroimaging characteristics of schizophrenia patients with large, rare copy number deletions Psychiatry Research-neuroimaging. ,vol. 224, pp. 311- 318 ,(2014) , 10.1016/J.PSCYCHRESNS.2014.10.006
Hans Rasmussen, Bjorn H. Ebdrup, David Erritzoe, Bodil Aggernaes, Bob Oranje, Jan Kalbitzer, Lars H. Pinborg, William F. C. Baaré, Claus Svarer, Henrik Lublin, Gitte M. Knudsen, Birte Glenthoj, Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine Psychopharmacology. ,vol. 213, pp. 583- 592 ,(2011) , 10.1007/S00213-010-1941-5
Helio Elkis, Treatment-Resistant Schizophrenia Psychiatric Clinics of North America. ,vol. 30, pp. 511- 533 ,(2007) , 10.1016/J.PSC.2007.04.001
Stefan Leucht, Andrea Cipriani, Loukia Spineli, Dimitris Mavridis, Deniz Örey, Franziska Richter, Myrto Samara, Corrado Barbui, Rolf R Engel, John R Geddes, Werner Kissling, Marko Paul Stapf, Bettina Lässig, Georgia Salanti, John M Davis, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis The Lancet. ,vol. 382, pp. 951- 962 ,(2013) , 10.1016/S0140-6736(13)60733-3
Jian-Ping Zhang, Anil K Malhotra, Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction Expert Opinion on Drug Metabolism & Toxicology. ,vol. 7, pp. 9- 37 ,(2011) , 10.1517/17425255.2011.532787